Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–522 of 522 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Viread Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Quantification of Estradiol's Impact on Nucleotides in Cellular Populations of the Lower GI Tract

NCT03917420
View directory record Official record
Conditions
HIV/AIDS
Interventions
Tenofovir 300Mg Oral Tablet, Emtricitabine 200 MG
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Nov 15, 2026, 5:04 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety, Tolerability and Pharmacokinetic Study of a Single Dose of CMX157 in Healthy Volunteers

NCT01080820
View directory record Official record
Conditions
Healthy
Interventions
CMX157, Placebo, Viread
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 4, 2011 · Synced Nov 15, 2026, 5:04 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Sustainable Healthcenter Implementation PrEP Pilot Study

NCT02074891
View directory record Official record
Conditions
HIV Chemoprophylaxis, HIV Preexposure Prophylaxis
Interventions
coformulated TDF/FTC
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
1,420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Jackson, Mississippi + 1 more
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Nov 15, 2026, 5:04 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Volunteers

NCT03596697
View directory record Official record
Conditions
Hepatitis B, Infectious Disease, Liver Diseases
Interventions
CRV431, Placebo, TDF
Drug
Lead sponsor
Hepion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
3
States / cities
Tempe, Arizona • Lincoln, Nebraska • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Nov 15, 2026, 5:04 AM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Validation of a Urine Assay to Measure Tenofovir Levels in Patients Taking Tenofovir Alafenamide

NCT03350672
View directory record Official record
Conditions
Hiv
Interventions
FTC/TAF
Drug
Lead sponsor
Philadelphia Fight
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 30, 2021 · Synced Nov 15, 2026, 5:04 AM EST
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIV

NCT01602822
View directory record Official record
Conditions
HIV
Interventions
Tenofovir DF and Emtricitabine; Ritonavir-boosted Atazanavir
Drug
Lead sponsor
Kenneth H. Mayer, MD
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Nov 15, 2026, 5:04 AM EST
Recruiting Phase 2 Interventional

A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1

NCT07645287
View directory record Official record
Conditions
HIV-1-infection
Interventions
GS-3242 Tablet, GS-3242 Injection, Lenacapavir Tablet, Lenacapavir Injection, B/F/TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
49
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 44 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 15, 2026, 5:04 AM EST
Recruiting Phase 2 Interventional

Antiviral Clinical Trial for Long Covid-19

NCT06511063
View directory record Official record
Conditions
Long Covid
Interventions
tenofovir disoproxil/emtricitabine, Selzentry, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Nov 15, 2026, 5:04 AM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

ENLIGHTEN: Establishing Novel Antiretroviral (ARV) Imaging for Hair to Elucidate Non-Adherence

NCT03218592
View directory record Official record
Conditions
HIV/AIDS
Interventions
Maraviroc Pill, Dolutegravir Pill, Truvada Pill
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 22, 2019 · Synced Nov 15, 2026, 5:04 AM EST
Completed Phase 2 Interventional Results available

Interventions for HIV Negative Men and Women Who Have High-risk Suspected Exposure to HIV

NCT00949234
View directory record Official record
Conditions
HIV Prevention, HIV Infections
Interventions
tenofovir + emtricitabine, lopinavir/ritonavir
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2017 · Synced Nov 15, 2026, 5:04 AM EST
Completed Phase 2 Interventional

A Comparison of Adefovir and Tenofovir for the Treatment of Lamivudine-Resistant Hepatitis B Virus in People With HIV

NCT00033163
View directory record Official record
Conditions
HIV Infections, Hepatitis B
Interventions
Adefovir dipivoxil, Tenofovir disoproxil fumarate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
15
States / cities
Sacramento, California • San Francisco, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Nov 15, 2026, 5:04 AM EST
Completed Phase 4 Interventional Accepts healthy volunteers

The Stay Study: A Demonstration Project Advancing PrEP Delivery in the San Francisco Bay Area Transgender Community

NCT03120936
View directory record Official record
Conditions
Transgender Persons, Pre-Exposure Prophylaxis
Interventions
Emtricitabine / Tenofovir Disoproxil Oral Tablet, PrEP support
Drug · Behavioral
Lead sponsor
Public Health Foundation Enterprises, Inc.
Other
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
5
States / cities
Fremont, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Nov 15, 2026, 5:04 AM EST
Completed Phase 3 Interventional Results available

Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Positive for Hepatitis B e Antigen

NCT01940471
View directory record Official record
Conditions
HBeAg-positive Chronic Hepatitis B
Interventions
TAF, TDF, TAF Placebo, TDF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
875 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
15
States / cities
Los Angeles, California • Palo Alto, California • Pasadena, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Nov 15, 2026, 5:04 AM EST
Terminated No phase listed Observational Results available

Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

NCT04518228
View directory record Official record
Conditions
HIV, Tuberculosis
Interventions
Bictegravir (BIC), Tenofovir alafenamide (TAF), Long-acting injectable formulation of cabotegravir (CAB LA), Dolutegravir (DTG), Atazanavir/ritonavir (ATV/r), Darunavir/ritonavir (DRV/r), Lopinavir/ritonavir (LPV/r), Cobicistat, Ritonavir, First-Line TB Treatment, Second-Line TB Treatment, Doravirine (DOR)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
13
States / cities
Los Angeles, California • San Diego, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Nov 15, 2026, 5:04 AM EST
Completed Not applicable Interventional

A Compassionate Use Study of Tenofovir Disoproxil Fumarate as Treatment for HIV Infection

NCT00002453
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir disoproxil fumarate
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Foster City, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 15, 2026, 5:04 AM EST
Completed Phase 3 Interventional

New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects

NCT00044577
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus I, HIV Infection
Interventions
abacavir/lamivudine, abacavir, lamivudine, tenofovir
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
30
States / cities
Los Angeles, California • Oakland, California • Fort Lauderdale, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Nov 15, 2026, 5:04 AM EST
Terminated Phase 3 Interventional Results available

Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1

NCT01345630
View directory record Official record
Conditions
HIV-1
Interventions
Maraviroc, Emtricitabine/tenofovir, darunavir/ritonavir 800/100 mg, placebo for emtricitabine/tenofovir, placebo for maraviroc
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
84
States / cities
Birmingham, Alabama • Hobson City, Alabama • Hayward, California + 45 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Nov 15, 2026, 5:04 AM EST
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Integrated Care Versus Usual Care for Opioid Use Disorder and Infectious Diseases in Veterans

NCT06766331
View directory record Official record
Conditions
Opioid Use Disorder, HIV, Hepatitis C Virus, Gonorrhea, Chlamydia, Syphilis, Sexually Transmitted Infection, Integrated Care, Medications for Opioid Use Disorder
Interventions
Integrated care
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2028 – 2029
U.S. locations
1
States / cities
Northport, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Nov 15, 2026, 5:04 AM EST